Orally active PDE4 inhibitor with therapeutic potential

European Journal of Medicinal Chemistry

Volumn 39, Issue 7, 2004, Pages 555-571

  Ochiai, Hiroshi ^a   Ohtani, Tazumi ^a   Ishida, Akiharu ^a   Kishikawa, Katuya ^a   Yamamoto, Susumu ^a   Takeda, Hiroshi ^a   Obata, Takaaki ^a   Nakai, Hisao ^a   Toda, Masaaki ^a  

^a ONO PHARMACEUTICAL CO   (Japan)

Author keywords

Bicyclo 3 3 0 octane; Orally active; PDE4 inhibitor; Spatial arrangement; Three pharmacophores

Indexed keywords

5 CYANO 5 (3 ETHOXY 4 METHOXYPHENYL) N HYDROXYOCTAHYDROPENTALENE 2 CARBOXAMIDE; 5 CYANO 5 (3 ETHOXY 4 METHOXYPHENYL)OCTAHYDROPENTALENE 2 CARBOXYLIC ACID; 5 CYANO 5 (3 ISOPROPOXY 4 METHOXYPHENYL)OCTAHYDROPENTALENE 2 CARBOXYLIC ACID; 5 CYANO 5 (3,4 DIMETHOXYPHENYL) N HYDROXYOCTAHYDROPENTALENE 2 CARBOXAMIDE; 5 CYANO 5 (3,4 DIMETHOXYPHENYL)OCTAHYDROPENTALENE 2 CARBOXYLIC ACID; 5 CYANO 5 [3 (2,3 DIHYDRO 1H INDEN 2 YLOXY) 4 METHOXYPHENYL] N HYDROXYOCTAHYDROPENTALENE 2 CARBOXAMIDE; 5 CYANO 5 [3 (2,3 DIHYDRO 1H INDEN 2 YLOXY) 4 METHOXYPHENYL] OCTAHYDROPENTALENE 2 CARBOXYLIC ACID; 5 CYANO 5 [3 (CYCLOBUTYLOXY) 4 METHOXYPHENYL] N HYDROXYOCTAHYDROPENTALENE 2 CARBOXAMIDE; 5 CYANO 5 [3 (CYCLOBUTYLOXY) 4 METHOXYPHENYL]OCTAHYDROPENTALENE 2 CARBOXYLIC ACID; 5 CYANO 5 [3 (CYCLOHEXYLOXY) 4 METHOXYPHENYL] N HYDROXYOCTAHYDROPENTALENE 2 CARBOXAMIDE; 5 CYANO 5 [3 (CYCLOHEXYLOXY) 4 METHOXYPHENYL]OCTAHYDROPENTALENE 2 CARBOXYLIC ACID; 5 CYANO 5 [3 (CYCLOPENTYLOXY) 4 METHOXYPHENYL] N HYDROXYOCTAHYDROPENTALENE 2 CARBOXAMIDE; 5 CYANO 5 [3 (CYCLOPENTYLOXY) 4 METHOXYPHENYL]OCTAHYDROPENTALENE 2 CARBOXYLIC ACID; 5 CYANO 5 [3 (CYCLOPROPYLMETHOXY) 4 METHOXYPHENYL] N HYDROXYOCTAHYDROPENTALENE 2 CARBOXAMIDE; 5 CYANO 5 [3 (CYCLOPROPYLMETHOXY) 4 METHOXYPHENYL]OCTAHYDROPENTALENE 2 CARBOXYLIC ACID; 5 CYANO 5 [4 METHOXY 3 (3,3,3 TRIFLUOROPROPOXY)PHENYL]OCTAHYDROPENTALENE 2 CARBOXYLIC ACID; 5 CYANO 5 [4 METHOXY 3 (TETRAHYDRO 2H PYRAN 4 YLOXY)PHENYL] OCTAHYDROPENTALENE 2 CARBOXYLIC ACID; 5 CYANO 5 [4 METHOXY 3 [4 (METHYLSULFANYL)BUTOXYPHENYL]]OCTAHYDROPENTALENE 2 CARBOXYLIC ACID; 5 CYANO N HYDROXY 5 (3 ISOPROPOXY 4 METHOXYPHENYL)OCTAHYDROPENTALENE 2 CARBOXAMIDE; 5 CYANO N HYDROXY 5 [4 METHOXY 3 (3,3,3 TRIFLUOROPROPOXY)PHENYL] OCTAHYDROPENTALENE 2 CARBOXAMIDE; 5 CYANO N HYDROXY 5 [4 METHOXY 3 (TETRAHYDRO 2H PYRAN 4 YLOXY)PHENYL]OCTAHYDROPENTALENE 2 CARBOXAMIDE; 5 CYANO N HYDROXY 5 [4 METHOXY 3 [4 (METHYLSULFANYL)BUTOXY]PHENYL] OCTAHYDROPENTALENE 2 CARBOXAMIDE; AMIDE; BICYCLO[3.3.0]OCTANE DERIVATIVE; CARBOXYLIC ACID DERIVATIVE; CILOMILAST; CYCLOHEXANE; NITRILE; PHOSPHODIESTERASE IV INHIBITOR; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; BRONCHOSPASM; CHEMICAL REACTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFECT; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; GUINEA PIG; IC 50; ISOMER; MALE; NONHUMAN; PHARMACOPHORE; RAT; REACTION ANALYSIS; SPECIES DIFFERENCE; STEREOCHEMISTRY; STOMACH EMPTYING; STRUCTURE ACTIVITY RELATION;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ADMINISTRATION, ORAL; ANIMALS; BRONCHOCONSTRICTION; FERRETS; GASTRIC EMPTYING; GUINEA PIGS; HUMANS; LIPOPOLYSACCHARIDES; MALE; PHOSPHODIESTERASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR NECROSIS FACTOR-ALPHA; U937 CELLS;

EID: 3242690751     PISSN: 02235234     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejmech.2004.02.010     Document Type: Article

References (20)

1. Essayan D.M. J. Allergy Clin. Immunol. 108:2001;671-680
2. Houslay M.D. Prog. Nucleic Acid Res. Mol. Biol. 69:2001;249-315
3. Teixeira M.M., Gristwood R.W., Cooper N., Hellewell P.G. Trends Pharmacol. Sci. 18:1997;164-170
4. Burnouf C., Pruniaux M.P. Curr. Pharm. Des. 8:2002;1255-1296
5. Norman P. Exp. Opin. Ther. Patents. 12:2002;93-111
6. Dyke H.J., Montana J.G. Exp. Opin. Investig. Drugs. 11:2002;1-13
7. Duplantier A.J., Biggers M.S., Chambers R.J., Cheng J.B., Cooper K., Damon D.B., Eggler J.F., Kraus K.G., Marfat A., Masamune H., Pillar J.S., Shirley J.T., Umland J.P., Watson J.W. J. Med. Chem. 39:1996;120-125
8. Barnette M.S., Grous M., Cieslinski L.B., Burman M., Christensen S.B., Torphy T.J. J. Pharmacol. Exp. Ther. 273:1995;1396-1402
9. Christensen S.B., Guider A., Forster C.F., Gleason J.G., Bender P.E., Karponski J.M., Dewolf W.E., Barnette M.S., Underwood D.C., Griswold D.E., Cieslinski L.B., Burman M., Bochnowicz S., Osborn R.R., Manning C.D., Grous M., Hillegas L.M., Bartus J.O., Ryan M.D., Eggleston D.S., Haltiwanger R.C., Torphy T.J. J. Med. Chem. 41:1998;821-835
10. Muller T., Engels P., Fozard J.R. Trends Pharmacol. Sci. 17:1996;294-298
11. Andres J.I., Alonso J.M., Diaz A., Fernandez J., Iturrino L., Martinez P., Matesanz E., Freyne E.J., Deroose F., Boeckx G., Petit D., Diels G., Megens A., Somers M., Van Wauwe J., Stoppie P., Cools M., De Clerck F., Peeters D., De Chaffoy D. Bioorg. Med. Chem. Lett. 12:2002;653-658
12. Hersperger R., Dawson J., Mueller T. Bioorg. Med. Chem. Lett. 12:2002;233-235
13. Groneberg R.D., Burns C.J., Morrissette M.M., Ullrich J.W., Morris R.L., Darnbrough S., Diuric S.W., Condon S.M., McGeeham G.M., Lahaudiniere R., Neuenschwander K., Scotese A.C., Kline J.A. J. Med. Chem. 42:1999;541-544
14. Kleinman E.F., Campbell E., Giordano L.A., Cohan V.L., Jenkinson T.H., Cheng J.B., Shirley J.T., Pettipher E.R., Salter E.D., Hibbs T.A., Dicapua F.M., Bordner J. J. Med. Chem. 41:1998;266-270
15. Nakagawa N., Obata T., Kobayashi T., Okada Y., Nambu F., Terawaki T., Aishita H. Jpn. J. Pharmacol. 60:1992;217-225
16. Nakagawa N., Obata T., Kobayashi T., Okada Y., Nambu F., Terawaki T., Furuya T., Muryobayashi K., Sawada M., Aishita H. Eur. J. Pharmacol. 235:1993;211-219
17. Brideau C., Staden C.V., Sthyler A., Rodger I.W., Chan C.C. Br. J. Pharmacol. 126:1999;979-988
18. Sheldrick G.M. Sheldrick G.M., Kruger C., Goddard R. Crystallographic Computing 3. 1985;175-189 Oxford University Press
19. Crystal Structure Analysis Package. 1985 & 1999;Molecular Structure Corporation
20. Reeves M.L., Leigh B.K., England P.J. Biochem. J. 241:1987;535-541